Regeneron and Sanofi Announce FDA Approval of Praluent alirocumab Injection the First PCSK9 Inhibitor in the U.S. for the Treatment of High LDL Cholesterol in Adult Patients

TARRYTOWN N.Y. and PARIS July 24 2015 PRNewswire &160;Regeneron Pharmaceuticals Inc. NASDAQ REGN and Sanofi today announced that the U.S. Food and Drug Administration FDA approved Praluent&174; alirocumab Injection the first FDAapproved treatment i...